Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.63 |
| ▸ | GABRP | O00591 | 1/20 | 0.60 |
| ▸ | GABRD | O14764 | 1/20 | 0.60 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.60 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.60 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.60 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.60 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.60 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.60 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.60 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.60 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.60 |
| ▸ | GABRE | P78334 | 1/20 | 0.60 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.60 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.60 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.60 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8613887 | 0.86 | GABRP (0.63) | SLC6A4GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL16801569 | 0.86 | SLC6A4 (0.71) | SLC6A4HTR6SLC6A2SLC6A3HTR1A | |
| SCHEMBL7850245 | 0.86 | GABRP (0.82) | SLC6A4GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL3222980 | 0.85 | GABRP (0.62) | SLC6A4GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL892861 | 0.85 | GABRP (0.62) | SLC6A4GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL1231869 | 0.85 | GABRP (0.62) | SLC6A4GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL12285689 | 0.85 | GABRP (0.62) | SLC6A4GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL30567971 | 0.85 | GABRP (0.62) | SLC6A4GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL6345407 | 0.85 | SLC6A4 (0.69) | SLC6A4HTR6SLC6A2SLC6A3HTR1A | |
| SCHEMBL7852403 | 0.84 | GABRP (0.48) | SLC6A4GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945213-A2 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-23 | — | — | EP | disclosed |
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| WO-2007050381-A2 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050381-A2 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-03 | — | — | WO | disclosed |
| EP-1598068-A1 | Antipsychotic heterocycle compounds | Bristol-Myers Squibb Company (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1242072-A4 | ANTIPSYCHOTIC HETEROCYCLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6476051-B2 | FOR THERAPY OF PSYCHOSIS, ACUTE MANIA, MILD ANXIETY STATES, OR DEPRESSION IN COMBINATION WITH PSYCHOTIC EPISODES | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-05 | — | — | US | disclosed |
| EP-1242072-A1 | ANTIPSYCHOTIC HETEROCYCLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020072611-A1 | Antipsychotic heterocycle compounds | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-13 | — | — | US | disclosed |
| WO-2001043740-A1 | ANTIPSYCHOTIC HETEROCYCLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072611-A1 | Antipsychotic heterocycle compounds | HTR2C, DRD2, HTR1A | SLC6A4 60/4885GABRP 293/4885GABRD 473/4885 |
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | OGFRL1, OPRL1, ORMDL3 | SLC6A4 931/4885GABRP 366/4885GABRD 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.